IBIO - iBio, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.7899
-0.0250 (-3.07%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.8149
Open0.8609
Bid0.7700 x 1800
Ask0.8800 x 900
Day's Range0.7800 - 0.8700
52 Week Range0.7500 - 47.0000
Volume336,426
Avg. Volume176,122
Market Cap10.341M
Beta-1.33
PE Ratio (TTM)N/A
EPS (TTM)-1.6420
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    iBio Establishes Strategic Commercial Relationship with CC-Pharming Ltd. of Beijing, China

    NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced the commencement of a strategic commercial relationship with CC-Pharming Ltd. of Beijing, China for joint development of products and manufacturing facilities for the Chinese biopharmaceutical market, utilizing iBio’s technology. The first product focus selected pursuant to the Master Joint Development Agreement executed between iBio and CC-Pharming will be a therapeutic antibody, with additional, mutually selected products to be added to the venture as it proceeds.

  • ACCESSWIRE20 days ago

    Free Technical Research on Nektar Therapeutics and Three More Biotech Equities

    On Tuesday, June 26, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: iBio Inc. (NYSE AMER: IBIO), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), Nektar Therapeutics (NASDAQ: NKTR), and Oragenics Inc. (NYSE AMER: OGEN).

  • GlobeNewswire20 days ago

    iBio, Inc. Closes $16,000,000 Public Offering

    IBIO, INC. (NYSE AMERICAN:IBIO) (“IBIO” OR THE “COMPANY”), today announced that it has closed its previously announced underwritten public offering with expected total gross proceeds of approximately $16,000,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) 4,350,000 shares of Common Stock at $0.90 per share, (ii) 6,300 shares of Series A Convertible Preferred Stock, with a stated value of $1,000 per preferred share, and convertible into an aggregate of 7,000,000 shares of Common Stock at $0.90 per share, (iii) 5,785 shares of Series B Convertible Preferred Stock, with a stated value of $1,000 per preferred share, and convertible into an aggregate of 6,427,778 shares of Common Stock at $0.90 per share.

  • GlobeNewswire25 days ago

    iBio, Inc. Prices $16,000,000 Public Offering

    NEW YORK, June 22, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” OR THE “COMPANY”), today announced the pricing of an underwritten public offering with expected total gross proceeds of approximately $16,000,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) 4,350,000 shares of Common Stock at $0.90 per share, (ii) 6,300 shares of Series A Convertible Preferred Stock, with a stated value of $1,000 per preferred share, and convertible into an aggregate of 7,000,000 shares of Common Stock at $0.90 per share, (iii) 5,785 shares of Series B Convertible Preferred Stock, with a stated value of $1,000 per preferred share, and convertible into an aggregate of 6,427,777 shares of Common Stock at $0.90 per share.

  • GlobeNewswirelast month

    iBio, Inc. Announces Completion of 1-For-10 Reverse Stock Split

    IBIO, INC. (NYSE AMERICAN:IBIO) (“IBIO” OR THE “COMPANY”) announced today that its previously announced 1-for-10 reverse stock split of common stock became effective today at 4:10 p.m. (Eastern Time) (the “Effective Time”).  The Company’s common stock will continue to trade on the NYSE American under the symbol “IBIO” under a new CUSIP number: 451033 203. At the Effective Time, every 10 issued and outstanding shares of common stock were combined and converted into one share of common stock.

  • GlobeNewswirelast month

    iBio, Inc. Reports on NYSE American Noncompliance Notice and Compliance Plan

    IBIO, INC. (NYSE AMERICAN:IBIO) (“IBIO” OR THE “COMPANY”) announced today that on June 6, 2018, the Company received a letter from NYSE American LLC (“NYSE American” or the “Exchange”) stating that it is not in compliance with the continued listing standards as set forth in Section 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”), which applies if a listed company has stockholders’ equity of less than $6,000,000 and has sustained losses from continuing operations and/or net losses in its five most recent fiscal years.

  • GlobeNewswirelast month

    iBio and ONEWAY Diagnostica Develop New Products for Brazil

    NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced a joint product development, manufacturing and revenue sharing agreement with ONEWAY Diagnostica of Brazil for novel point of care diagnostic products initially focused on Zika and Chikungunya virus infections. ONEWAY Diagnostica will manage marketing, distribution and sales in Brazil.

  • Why iBio Inc’s (NYSEMKT:IBIO) Ownership Structure Is Important
    Simply Wall St.last month

    Why iBio Inc’s (NYSEMKT:IBIO) Ownership Structure Is Important

    I am going to take a deep dive into iBio Inc’s (AMEX:IBIO) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure of a companyRead More...

  • GlobeNewswire2 months ago

    iBio, Inc. Announces Reverse Stock Split

    NEW YORK, May 31, 2018-- IBIO, INC. announced today a reverse split of its Common Stock, par value $0.001 per share, at a ratio of 1 for 10, effective on June 8, 2018. The Company’ s common stock will ...

  • ACCESSWIRE2 months ago

    Complimentary Technical Snapshots on Heat Biologics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want a free Stock Review on HTBX sign up now at www.wallstequities.com/registration. Today, WallStEquities.com has selected the following stocks for review: Heat Biologics Inc. (NASDAQ: HTBX), Hemispherx Biopharma Inc. (NYSE AMER: HEB), iBio Inc. (NYSE: IBIO), and Idera Pharmaceuticals Inc. (NASDAQ: IDRA).

  • Should iBio Inc’s (NYSEMKT:IBIO) Recent Earnings Decline Worry You?
    Simply Wall St.3 months ago

    Should iBio Inc’s (NYSEMKT:IBIO) Recent Earnings Decline Worry You?

    After reading iBio Inc’s (AMEX:IBIO) latest earnings update (31 December 2017), I found it beneficial to look back at how the company has performed in the past and compare thisRead More...

  • iBio Inc (IBIO): Does -31.1% EPS Decline Lately Make It An Underperformer?
    Simply Wall St.7 months ago

    iBio Inc (IBIO): Does -31.1% EPS Decline Lately Make It An Underperformer?

    When iBio Inc (AMEX:IBIO) released its most recent earnings update (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of its industryRead More...

  • Capital Cube8 months ago

    ETFs with exposure to iBio, Inc. : November 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to iBio, Inc. Here are 5 ETFs with the largest exposure to IBIO-US. Comparing the performance and risk of iBio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube8 months ago

    ETFs with exposure to iBio, Inc. : November 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to iBio, Inc. Here are 5 ETFs with the largest exposure to IBIO-US. Comparing the performance and risk of iBio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • iBio, Inc. :IBIO-US: Earnings Analysis: Q1, 2018 By the Numbers : November 13, 2017
    Capital Cube8 months ago

    iBio, Inc. :IBIO-US: Earnings Analysis: Q1, 2018 By the Numbers : November 13, 2017

    Categories: Yahoo FinanceGet free summary analysis iBio, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of iBio, Inc. – Genocea Biosciences, Inc., Johnson & Johnson, Aviragen Therapeutics Inc, Newlink Genetics Corporation, Altimmune, Inc., Nektar Therapeutics, Achaogen, Inc., Emergent BioSolutions Inc. and Immunomedics, Inc. (GNCA-US, JNJ-US, ... Read more (Read more...)

  • Zacks Small Cap Research8 months ago

    AEMD: Upcoming FDA Meeting Expected to Define U.S. Regulatory Pathway

    Cash used in operating activities was $1.0M in Q2 and $2.1M in 1H 2018.  Relative to the balance sheet, AEMD exited Q2 with $920k in cash but subsequent to quarter-end, they raised $6.0M ($5.3M net) via a secondary equity offering (5.4M shares @ $1.10/share, with 100% warrant coverage: 5yrs, $1.10 strike).  AEMD expects current cash (i.e.